Symbiotec Pharmalab Ltd (SYMBIOTEC) Q2 FY27 Financial Results: PAT ₹14.1 & Revenue ₹218.2 Cr (3 announcements)

Investor Takeaways

• Revenue grew to ₹218.2 crores from ₹203.2 crores YoY
• Net Profit declined to ₹14.1 crores from ₹29.9 crores YoY
• Consolidated EBITDA fell to ₹45.2 crores from ₹58.0 crores YoY
• Net debt reduced to ₹326 crores post-IPO
• ⚠️ PAT decline of 53% YoY indicates near-term profitability pressure

Overall Tone: Neutral

Key Financial Highlights

What Changed

Symbiotec Pharmalab reported Q1FY27 revenue of ₹218.2 crores, up from ₹203.2 crores in Q1FY26, driven by 6% API growth and new business ramp-up. However, consolidated EBITDA declined to ₹45.2 crores from ₹58.0 crores YoY, and PAT dropped sharply to ₹14.1 crores from ₹29.9 crores. The company highlighted steady API margins (60% gross, 30% EBITDA) and progress on complex injectables and CDMO pipelines, including USFDA audits and first ANDA filing. Capex reached ₹68 crores in Q1, targeting ₹1,666 crores by FY27, with 61% allocated to revenue-generating projects. Net debt declined to ₹326 crores post-IPO proceeds. The filing reflects a strategic shift toward long-term growth through regulated API margins and sticky CDMO contracts, though near-term profitability is pressured by capex and ramp-up costs.

Peer Comparison

Symbiotec Pharmalab’s P/E ratio is not available in the provided data, while peers show elevated multiples (36.42–84.99), indicating market expectations of growth despite current profitability pressures.

Risks & Concerns

• PAT declined 53% YoY to ₹14.1 crores, signaling margin compression from strategic investments
• EBITDA fell 22% YoY to ₹45.2 crores, reflecting near-term cost pressures
• No specific risks identified beyond operational execution in filing

Quarterly Trend

The decline in OPM from 23.36% to 13.6% and PAT trajectory underscores near-term profitability challenges despite revenue growth.

Investor Takeaways

• Revenue grew to ₹2,181.50 crores from ₹2,031.72 crores YoY, reflecting 7.4% growth.
• Net profit increased to ₹175.32 crores from ₹160.11 crores YoY.
• ⚠️ No specific risks identified in this filing.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

What Changed

Symbiotec Pharmalab reported consolidated revenue of ₹2,181.50 crores for Q1 FY2026, up from ₹2,031.72 crores in Q1 FY2025, representing a 7.4% year-on-year increase. Net profit rose to ₹175.32 crores from ₹160.11 crores in the same quarter of the previous fiscal year. The results, approved by the Board on September 21, 2026, were unaudited and included disclosures related to the company's recent IPO and subsidiary performance. The filing confirms financials are preliminary and subject to auditor review. No additional financial metrics such as EBITDA or OPM were disclosed in this release.

Peer Comparison

Symbiotec Pharmalab’s market capitalization of ₹5,977.89 crores is significantly smaller than its peers, including Sun Pharma and Divis Labs, which have market caps exceeding ₹18,000 crores. Its P/B ratio of 7.34 is notably higher than typical industry norms, suggesting market expectations may be priced at a premium relative to book value. However, no profitability ratios or P/E are available for direct comparison.

Risks & Concerns

• No specific risks identified in this filing.

Quarterly Trend

Note: Quarterly trend data provided in the context refers to standalone quarterly performance and not consolidated figures. The data provided does not align with the consolidated revenue and profit figures reported in the filing. As per instructions, the Quarterly Trend section is omitted since the provided trend data (e.g., Q1FY26 revenue of ₹203.17 Cr) does not match the consolidated revenue of ₹2,181.50 Cr and is not comparable in scale or context. Including it would risk misrepresentation. Therefore, this section is excluded to maintain factual accuracy and compliance with the rule of using only provided, consistent data.

Overall Assessment: The company demonstrated growth in both revenue and net profit YoY, with financials approved by the Board under limited auditor review. The results reflect positive momentum but are based on unaudited data. Comparisons with peers highlight structural differences in scale and valuation. No risks were disclosed, but the lack of full profitability metrics and peer alignment in scale warrants cautious interpretation.